In vitro antibacterial activities of S-013420, a novel bicyclolide, against respiratory tract pathogens

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1433-1440

  Homma, Tomoyuki ^a   Fujimura, Takaji ^a   Maki, Hideki ^a   Yamano, Yoshinori ^a   Shimada, Jingoro ^b   Kuwahara, Shogo ^c  

^a SHIONOGI AND CO LTD   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bactericidal; Erythromycin resistance; Streptococci

Indexed keywords

9 ACETYLIMINO 3 DEHEXAPYRANOSYLOXY 9 DEOXO 3 OXO 6 O,11 O [2 [6 (1 PYRAZOLYL) 3 PYRIDINYLMETHOXYIMINO]PROPYLENE]ERYTHROMYCIN; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; TELITHROMYCIN; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; ANTIBIOTIC RESISTANCE; BACTERIA; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; JAPAN; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; MUTATION; RESPIRATORY TRACT INFECTION; TIME;

ANTI-BACTERIAL AGENTS; BACTERIA; DRUG RESISTANCE, BACTERIAL; HUMANS; JAPAN; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MUTATION; RESPIRATORY TRACT INFECTIONS; TIME FACTORS;

EID: 77954196298     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq147     Document Type: Article

References (29)

1. Volturo GA, Low DE, Aghababian R. Managing acute lower respiratory tract infections in an era of antibacterial resistance. Am J Emerg Med 2006; 24: 329-42.
2. Wierzbowski AK, Hoban DJ, Hisanaga T et al. The use of macrolides in treatment of upper respiratory tract infections. Curr Infect Dis Rep 2005; 7: 175-84.
3. Bozdogan B, Appelbaum PC. Macrolide resistance in streptococci and Haemophilus influenzae. Clin Lab Med 2004; 24: 455-75.
4. Farrell DJ, Canton R, Hryniewicz W. Trends in antibacterial resistance of Streptococcus pneumoniae: PROTEKT global years 1-5. Clin Microbiol Infect 2006; 12 Suppl 4: S1279-80.
5. Jenkins SG, Farrell DJ, Patel M et al. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect 2005; 51: 355-63.
6. Zhanel GG, Dueck M, Hoban DJ et al. Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 2001; 61: 443-98.
7. Scorneaux B, Arya A, Polemeropoulos M et al. In vitro and in vivo evaluation of EP-13420: a novel ketolide highly active against resistant pathogens and having exceptional pharmacokinetic properties in the dog. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-1191, p. 243. American Society for Microbiology, Washington, DC, USA.
8. Furuie H, Irie S, Saisho Y et al. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother 2010; 54: 866-70.
9. Fujimura T, Yoshida I, Itoh Y et al. Antimicrobial susceptibility of clinical isolates of aerobic Gram-positive cocci and anaerobic bacteria in 2004. Jpn J Chemother 2008; 56: 543-61.
10. Yoshida I, Fujimura T, Itoh Y et al. Antimicrobial susceptibility of clinical isolates of aerobic Gram-negative bacteria in 2004. Jpn J Chemother 2008; 56: 562-79.
11. Morosini MI, Cantón R, Loza E et al. Streptococcus pyogenes isolates with characterized macrolide resistance mechanisms in Spain: in vitro activities of telithromycin and cethromycin. J Antimicrob Chemother 2003; 52:50-5.
12. Reig M, Galan J, Baquero F et al. Macrolide resistance in Peptostreptococcus spp. mediated by ermTR: possible source of macrolide-lincosamide-streptogramin B resistance in Streptococcus pyogenes. Antimicrob Agents Chemother 2001; 45: 630-2.
13. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Seventh Edition: Approved Standard M7-A7. Wayne PA, USA: CLSI 2006.
14. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria-Seventh Edition: Approved Standard M11-A7 Wayne PA, USA: CLSI 2006.
15. Furneri PM, Marino A, Saija A et al. In vitro antimycoplasmal activity of oleuropein. Int J Antimicrob Agents 2002; 20: 293-6.
16. Method for in vitro determination of chlamydial susceptibility (minimum inhibitory concentration; MIC) to antimicrobial agents Chemotherapy Committee for Investigating Method on MIC of Chlamydia 1992; 40: 308-14.
17. Kohno S, Yamaguchi K, Tanigawara Y et al. 2007 The efficacy, the safety and the pharmacokinetics (PK) of S-013420, a bicyclolide in patients with community-acquired pneumonia (CAP) Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, Abstract L-485, p. 397. American Society for Microbiology, Washington, DC, USA.
18. Kaieda S, Yano H, Okitsu N et al. 2002 In vitro isolation of a Streptococcus pneumoniae mutant constitutively resistant to macrolides-lincosamide (ML) and characterization of its altered attenuator of the erm(B) gene. In: Abstracts of the Forty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA American Society for Microbiology, Washington, DC, USA.. Abstract C1-1580, p. 72.
19. B resistance phenotype. J Antimicrob Chemother 1997; 40: 85-90.
20. Faccone D, Andres P, Galas M et al. Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones. J Clin Microbiol 2005; 43: 5800-3.
21. Hsueh PR, Teng LJ, Wu TL et al. Telithromycin- and fluoroquinolone- resistant Streptococcus pneumoniae in Taiwan with high prevalence of 1440 resistance to macrolides and β-lactams: SMART program 2001 data. Antimicrob Agents Chemother 2003; 47: 2145-51.
22. Waites K, Johnson C, Gray B et al. Use of clindamycin disks to detect macrolide resistance mediated by ermB and mefE in Streptococcus pneumoniae isolates from adults and children. J Clin Microbiol 2000; 38: 1731-4.
23. Zhong P, Cao Z, Hammond R et al. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb Drug Resist 1999; 5: 183-8.
24. Inoue M, Sato Y, Okamoto R. Bacteriological study of telithromycin. Jpn J Antibiot 2003; 56: 674-80.
25. Douthwaite S, Hansen LH, Mauvais P et al. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol 2000; 36: 183-93.
26. Hansen LH, Mauvais P, Douthwaite S et al. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol 1999; 31: 623-31.
27. Xiong L, Korkhin Y, Mankin AS. Binding site of the bridged macrolides in the Escherichia coli ribosome. Antimicrob Agents Chemother 2005; 49: 281-8.
28. Xiong L, Shah S, Mauvais P et al. A ketolide resistance mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol Microbiol 1999; 31: 633-9.
29. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-24.